EBIOPARTICLE
DEAD

Serial Number

88813315

Owner

Angany Inc.

Attorney

Peter Kunin

Filing Date

Feb 27, 2020

Add to watchlist:

No watchlists yet
View on USPTO

EBIOPARTICLE Trademark

Serial Number: 88813315

EBIOPARTICLE is a trademark filed by Angany Inc. on February 27, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Angany Inc. (3 trademarks)

873 Rue Saint-Jean, suite 200
Quebec (Quebec) G1R1R2 , CA

Entity Type: 03

Trademark Details

Filing Date

February 27, 2020

Registration Date

Not Registered

Goods & Services

(Based on 44(d) Priority Application) (Based on Intent to Use) Protein arrays for medical diagnosis purposes; proteins arrays for therapeutic use for treating cancer, allergies, autoimmune disease, infection disease, and inflammatory disease; biopharmaceuticals for treatment of cancer, allergies, autoimmune disease, infection disease; pharmaceutical preparations for use in the treatment of allergy, cancer, infectious diseases and immune diseases; pharmacological preparations able to effect immunotherapy with specific attributes of potency and safety

(Based on 44(d) Priority Application) (Based on Intent to Use) Chemicals for use in the manufacture of pharmaceuticals; proteins for immunoassay for detection, for diagnostic purposes, for therapeutic purposes and for treatment of cancer, allergies, autoimmune disease, infection diseases; all of the foregoing expressly excluding biologically-derived particles that can be fluorescently-labeled for scientific research purposes

(Based on 44(d) Priority Application) (Based on Intent to Use) Development of pharmaceutical preparations and medicines; drug discovery services; software as a service (SAAS) services featuring artificial intelligence software for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining in the field of providing pharmaceutical products in order to create as many therapeutic different therapeutic agents deemed in the pharmaceutical industry and nanoparticles; platform as a service (PAAS) services featuring artificial intelligence software platforms for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining for use in the field of pharmacological and pharmaceutical products in order to create as many therapeutic different therapeutic agents deemed in the pharmaceutical industry and nanoparticles; platform as a service (PAAS) services featuring computer software platforms for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining for use in the field of pharmacological and pharmaceutical applications that is an immunomodulatory vector on which biologic targets determine the pertinence and use of these pharmacological agents

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Mar 9, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Mar 9, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 9, 2023 ABN2
ASSIGNED TO EXAMINER
Jan 17, 2023 DOCK
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Aug 25, 2022 GNS2
INQUIRY TO SUSPENSION E-MAILED
Aug 25, 2022 GNSI
SUSPENSION INQUIRY WRITTEN
Aug 25, 2022 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 25, 2022 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 24, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 24, 2022 GNSL
SUSPENSION LETTER WRITTEN
Feb 24, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 3, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 3, 2022 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jan 26, 2022 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 22, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 22, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 22, 2021 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 20, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 20, 2021 GNSL
SUSPENSION LETTER WRITTEN
Mar 20, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 22, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 22, 2021 CRFA
ASSIGNED TO LIE
Feb 22, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 18, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 18, 2020 GNRN
NON-FINAL ACTION E-MAILED
May 18, 2020 GNRT
NON-FINAL ACTION WRITTEN
May 18, 2020 CNRT
ASSIGNED TO EXAMINER
May 18, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 5, 2020 NWOS
NEW APPLICATION ENTERED
Mar 5, 2020 NWAP